Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
not yet, getting ready to read it now, honestly, when this came across my phone, I was like wtf, we got cash, dunno...got hold my comments until I read it through....
I thought that too. They have alot of cash on hand. Why put a Nr out that doesn't say any thing?
Did you read today's NR?
Thats the most ambiguous NR I think Ive ever read.
We're going to offer shares but we're not going to tell anyone anything about the offering, and we may not do it at all?
Anyone else read that the same way? Im surprised theyre doing any offering with the load of cash on hand.
next data set on phase 2 should be out in the next couple months. If we have continued show of ASH numbers - then I believe we become best in class. If that happens - watch for partnership news IMO...
That sounds great I'm lookin to buy some today!
2/22/2012 YM Biosciences recent weakness creates buying opportunity, says Wells Fargo
Wells Fargo believes that investors are failing to recognize the potential of YM's lead drug as a treatment for indications other than myelofibrosis. However, the firm believes that YM is undervalued based on the drug's potential in myelofibrosis alone, and it maintains an Outperform rating on the stock.
Nope, just more of the same. Stock runs up prior to the monthlies expiring, stays just under the $2.50 strike and provides a chance to sell more calls. Then it retreats. YMI continues to provide opportunities for everyone.
For the long term shareholder, hopefully some day soon the pattern will break and the stock will start rising toward the $4-$5 area. Might take some time, and most likely will continue to be volatile in the interim.
Sorry, I haven't seen it and it was just posted this morning...
I THINK THIS IS OLD NEWS
News for 'YMI' - (YM BioSciences Reports Q2 2012 Operational and Financial Results)
Feb 15, 2012 (Close-Up Media via COMTEX) -- YM BioSciences Inc., a drug
development company advancing a diverse portfolio of hematology and cancer
related products, reported operational and financial results for its second
quarter of fiscal 2012, ended December 31, 2011.
"JAK inhibitors may ultimately prove valuable in the treatment of a wide range
of blood disorders, cancers and inflammatory diseases, representing an immense
opportunity for this emerging drug class. We recently reported multicenter data
for our lead JAK inhibitor, CYT387, establishing its competitive safety and
efficacy profile in patients with myelofibrosis," said Dr. Nick Glover,
President and CEO of YM BioSciences. "The strength of our data positions us well
to select the optimal course to further advance this opportunity."
In a release on February 9, the Company reported updated results from the Phase
I/II study of CYT387 in 166 patients with myelofibrosis were presented in a
poster session at the 53rd Annual Meeting of the American Society of Hematology
held in San Diego in December 2011. CYT387 demonstrated an ability to render and
maintain anemic myelofibrosis patients transfusion independent for
clinically-relevant periods while also producing significant and durable
improvements in their splenomegaly and constitutional symptoms. CYT387 was
generally safe and well tolerated in myelofibrosis patients for dosing periods
up to and exceeding two years, with minimal treatment-related myelosuppression
observed.
Financial Results (CDN dollars)
The interim consolidated financial statements and comparative information for
the second quarter of fiscal 2012 have been prepared in accordance with
International Financial Reporting Standards (IFRS). Previously, up to June 30,
2011, the Company prepared its Interim and Annual Consolidated Financial
Statements in accordance with Canadian Generally Accepted Accounting Principles
("Canadian GAAP").
Revenue from out-licensing for the second quarter of fiscal 2012, ended December
31, 2011, was $0.4 million compared with $0.3 million for the second quarter of
fiscal 2011. Revenue from out-licensing for the first six months of fiscal 2012
was $0.6 million and comparable to $0.6 million for the first six months of
fiscal 2011.
Net finance income was $1.5 million for the second quarter of fiscal 2012
compared to net finance costs of $4.6 million for the second quarter of fiscal
2011. Net finance income was $9.0 million for the first six months of fiscal
2012 compared to net finance costs of $8.3 million for the first six months of
fiscal 2011. Under IFRS, warrants denominated in a different currency than the
Company's functional currency must be classified as a financial liability and
measured at fair value, with changes reflected in profit or loss. The change in
net finance income during the second fiscal quarter is primarily attributed to a
change of $6.0 million in the fair value adjustment for USD warrants. For the
first six months of fiscal 2012, the Company incurred a gain of $7.3 million
compared to a loss of $7.5 million for the six months ended December 31, 2010 on
the revaluation of warrants.
Licensing and product development expenses were $7.3 million for the second
quarter of fiscal 2012 compared with $5.2 million for the second quarter of
fiscal 2011. Licensing and product development expenses were $13.7 million for
the first six months of fiscal 2012 compared with $10.9 million for the first
six months of fiscal 2011. Development expenses for CYT387 increased due to the
expansion of the Phase I/II clinical trial in myelofibrosis, start-up costs
associated with the BID (twice-daily dosing) study, pre-clinical development
activities, and manufacturing of drug for these programs. Expenses for
nimotuzumab continued to decrease.
General and administrative expenses were $1.2 million for the second quarter of
fiscal 2012 compared to $2.7 million for the second quarter of fiscal 2011.
General and administrative expenses were $3.3 million for the first six months
of fiscal 2012 compared to $5.0 million for the first six months of fiscal 2011,
primarily due to severance and restructuring costs in 2010.
Net loss for the second quarter of fiscal 2012 was $6.6 million ($0.06 per
share) compared to $12.3 million ($0.14 per share) for the same period last
year.
As at December 31, 2011 the Company had cash and short-term deposits totaling
$67.9 million and accounts payables and accrued liabilities totaling $3.7
million compared to $79.7 million and $4.4 million respectively at June 30,
2011. Management believes that the cash and short-term deposits at December 31,
2011 are sufficient to support the Company's activities for at least the next 18
months.
As at December 31, 2011 the Company had 116,711,448 common shares and 7,366,418
warrants outstanding.
((Comments on this story may be sent to newsdesk@closeupmedia.com))
This thing is about to make a huge move... up or down. No idea yet. On watch
expect some news by the end of the week.......huge blocks going thru. Cat's out of the bag imo
It's got the same pattern that it had 2 days ago. 2 days ago it spiked up around 1pm after 3 hours of rising consolidation. I'm guessing it spikes up around 1:30 or 2 today.
Looks like it took a one day breather....heading up again to a truer valuation imo.....
yeah, its' picked up a lot!
Really what are you looking at?
volume has dried up. I think this goes down to the mid $1.80s before heading higher.
I don't know if it had anything to do with that news. Looks to me like there's been alot of slow deliberate accumulation since ASH and it was getting wound pretty tight. This was long overdue....GLTA
Called $YMI here
http://p.twimg.com/AjfexDmCMAA_BE8.png
now it looks like this
http://p.twimg.com/AkcpTRaCQAA5Qtc.png
visit
http://www.futurefairvalue.com/
Called $YMI here
http://p.twimg.com/AjfexDmCMAA_BE8.png
now it looks like this
http://p.twimg.com/AkcpTRaCQAA5Qtc.png
visit
http://www.futurefairvalue.com/
Wow! I was wondering when this news would start the rise. YMI has some excellent potential!
YMI breaking out on last weeks news:
January 23, 2012
09:16 EDT YMI
theflyonthewall.com: YM Biosciences reported compelling data, says Roth Capital
Roth Capital believes that YM reported differentiated efficacy data, especially with regard to positive anemia responses, at ASH. The firm thinks that the company will land a major partnership n 1H12 and it reiterates a $6 target and Buy rating on the stock. :theflyo
1.70~1.72 has been a ceiling so far. Lets hope it breaks that soon.
enchated
News Breaks
January 23, 2012
09:16 EDT YMI
theflyonthewall.com: YM Biosciences reported compelling data, says Roth Capital
Roth Capital believes that YM reported differentiated efficacy data, especially with regard to positive anemia responses, at ASH. The firm thinks that the company will land a major partnership n 1H12 and it reiterates a $6 target and Buy rating on the stock.
YMI should start a new move higher....rare
Zacks is Buy on Ymi -
http://finance.yahoo.com/news/Zacks-Voice-People-highlights-zacks-3719664311.html?x=0
$YMI closed above 13 and 50 ema
http://p.twimg.com/AjfexDmCMAA_BE8.png
Imo chart is pointing towards $2 plus in the near future.
$YMI - Break Out signs - http://bit.ly/xyPfT4 - All signs point to $YMI
looks like we may finally be breaking out of the range we've been in for a few months. Volume is up...
just end of the year blues, IMO!
Where did the volume on this go? Very little movement last few days.
They currently run through about 6.5 million a quarter which means they are funded for the considerable future
I was just asking you if you have any idea about how much the Phase III study cost. Since you told they have 70M, I was wondering if that is enough or not.
Thanks
enchanted,
so you are asking me if I know the budget estimate for the phase III study? I don't know what that means, sorry!
if you are talking time, the latest I heard was quarter 1, 2012...
Do you have any estimate for the Phase III study?
Thanks
YMI - I THINK, BECAUSE OF ALL THE ANALYST UPGRADES RECENTLY, MARKET AND SHORT SELLERS ARE THINKING ABOUT POSSIBLE FINANCING COMING IN. EVEN IF THAT HAPPENS THE STOCK IS WAYYY UNDERVALUED.
IF PARTENRESHIP NEWS COMES IN SHORTS WILL GET CRUSHED LIKE A HOT POTATO.
Its just my guess
What makes you think that? did you talk with the TA?
YM's Positive Results Have Incyte Investors Worried
by: EP Vantage December 15, 2011
YM BioSciences (YMI) is the big winner emerging from the American Society of Hematology annual meeting. Positive phase I/II data presented for its Janus-kinase-1/2 (Jak1/2) inhibitor CYT387 in myelofibrosis impressed enough to drive shares up 15% to $1.69 on Tuesday and damage likely competitor Incyte (INCY).
Pharmacyclics (PCYC) also bounced back from profit-taking following its licensing deal with Johnson & Johnson (JNJ) on strong signs of efficacy for PCI-32765 in chronic lymphocytic leukaemia and mantle cell lymphoma. On the negative side, confirmation of four drug-related deaths in a mid-stage trial of Ariad’s (ARIA) ponatinib offset encouraging efficacy data; shares have slid 5% since Friday as hopes for a partnership and gaining accelerated approval have been tempered.
Second to market
Should it be approved by regulatory authorities, YM’s CYT387 would be the second JAK inhibitor to treat myelofibrosis following Incyte’s Jakafi, and as such needs to outperform in the clinic. Anemia among myelofibrosis patients is an indicator of poor life expectancy, so achieving improvements in hemoglobin levels and reducing transfusion rates is a major goal – in clinical trials 45% of patients taking Jakafi experienced serious anemia necessitating medical intervention such as transfusion (Event – Jitters ahead of Incyte approval, October 14, 2011).
Sixty-eight of the 166 patients in the CYT387 trial were dependent on transfusions at the start of their treatment cycles, and of those 54% no longer needed transfusions after 12 weeks of treatment, consistent with interim findings presented at Asco and meeting the highest expectations of observers (ASH Preview - Novel drug classes facing important tests, December 7, 2011).
In the treatment arm taking the highest dose of the pill, 300mg daily, 65% of anemic patients were transfusion free. In a call with investors, chief executive Nick Glover said YM is planning on pushing ahead with that dosage in phase III trials hoped to begin next year.
Tuesday’s 15% share price surge is encouraging; however, the Canadian group’s market capitalisation is down nearly one-third this year. Since it has reached the key end of phase II milestone, partnership talks are likely to accelerate; any news of a licensing deal would help drive prices higher.
Meanwhile, Incyte’s investors clearly were worried by the competition; shares in the Delaware company fell 5% to $13.62 on Tuesday.
Good news not done
Whilst the recent signing of a $150m upfront licensing deal with J&J on PCI-32765 diverted some attention and reduced expectations on Pharmacyclics' Bruton’s tyrosine kinase (Btk) inhibitor, the release of data still generated investor excitement (J&J pays handsomely for first-in-class blood cancer drug, December 9, 2011). Shares rose 8% to $13.71 Tuesday following a spate of news in several types of blood cancers, the most advanced being in chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
The phase Ib/II data in CLL/SLL for the most advanced Btk in clinical development showed the candidate achieved an overall response rate of 67% in a 420mg daily dose group and 68% for those taking 840mg daily. At 12 months, 86% of patients were free of tumor progression. The company said the results support advancing the drug into phase III - a conclusion that J&J had clearly already come to.
More data needed
For Ariad, news of deaths in the phase II ponatinib trial in chronic myeloid leukaemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) was disclosed in the ASH abstracts released in November. Confirmation that four deaths were drug-related will give potential partners pause for thought.
Efficacy looks promising, with 47% of chronic phase patients achieving a major cytogenetic response. Of the four deaths possibly or probably related to ponatinib treatment, three had advanced-phase CML or Ph+ ALL. Causes were pneumonia, hemorrhage and cardiac arrest, and all had complex medical conditions.
Further safety data will shed light on the significance of those deaths. As the results are preliminary, and as the Massachusetts company is recruiting for a second phase II trial in ALL, more will be known in the near future on the emerging safety profile of this dual inhibitor of tyrosine kinase and fibrolast growth factor receptor. Potential partners could well chose to wait.
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
923
|
Created
|
07/17/05
|
Type
|
Free
|
Moderators |
YMI BioSciences, Inc.
CYT997 has completed two Phase I studies in advanced solid tumors and is currently being studied in a Phase II clinical trial in combination with chemotherapy in patients with relapsed glioblastoma multiforme. Results from the intravenous Phase I dose escalation study were published in the British Journal of Cancer (Lickliter et al, 2010), and demonstrated clinically meaningful disease stabilization in the majority of patients treated. Data showed that CYT997 administration was associated with changes in plasma and imaging biomarkers consistent with vascular disruption in tumors. Magnetic resonance imaging showed significant changes in tumor perfusion consistent with vascular disruption in some patients. Data from the Phase I oral study of CYT997 in patients with advanced cancer were reported at ASCO 2009 (Francesconi et al, 2009).
2011 2nd Quarter http://www.ymbiosciences.com/upload_files/YM_Q2_2011.pdf
2011 3rd Quarter http://www.otcmarkets.com/stock/YMI/news
2010 Annual Report 10-K http://www.ymbiosciences.com/upload_files/YM_AR_2010.pdf
Website http://www.ymbiosciences.com/
Yahoo Finance http://finance.yahoo.com/q/h?s=YMI
Google Finance http://finance.google.com/finance?client=ob&q=YMI
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |